UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro-inflammatory “FADDosome” Complex upon TRAIL Stimulation

Molecular cell, 2017-02, Vol.65 (4), p.715-729.e5

2017

Volltextzugriff (PDF)

Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model

International journal of pharmaceutics, 2018-10, Vol.549 (1-2), p.218-229

2018

Volltextzugriff (PDF)

The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2

Molecular cell, 2017-02, Vol.65 (4), p.730-742.e5

2017

Volltextzugriff (PDF)

TNF-alpha inhibition for the treatment of cardiac sarcoidosis

Seminars in arthritis and rheumatism, 2020-06, Vol.50 (3), p.546-552

2020

Volltextzugriff (PDF)

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

The Lancet (British edition), 2015-08, Vol.386 (9993), p.541-551

2015

Volltextzugriff (PDF)

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

The Lancet (British edition), 2020-04, Vol.395 (10230), p.1126-1136

2020

Volltextzugriff (PDF)

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

The Lancet (British edition), 2020-04, Vol.395 (10230), p.1115-1125

2020

Volltextzugriff (PDF)

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

The Lancet (British edition), 2018-12, Vol.392 (10163), p.2441-2451

2018

Volltextzugriff (PDF)

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

The Lancet (British edition), 2019-08, Vol.394 (10198), p.576-586

2019

Volltextzugriff (PDF)

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

The Lancet (British edition), 2018-08, Vol.392 (10148), p.650-661

2018

Volltextzugriff (PDF)

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

The Lancet (British edition), 2017-06, Vol.389 (10086), p.2304-2316

2017

Volltextzugriff (PDF)

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

The Lancet (British edition), 2017-06, Vol.389 (10086), p.2317-2327

2017

Volltextzugriff (PDF)

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

The Lancet (British edition), 2020-05, Vol.395 (10235), p.1496-1505

2020

Volltextzugriff (PDF)

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

The Lancet (British edition), 2020-01, Vol.395 (10217), p.53-64

2020

Volltextzugriff (PDF)

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

The Lancet (British edition), 2019-04, Vol.393 (10182), p.1699-1707

2019

Volltextzugriff (PDF)

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

The Lancet (British edition), 2017-07, Vol.390 (10093), p.457-468

2017

Volltextzugriff (PDF)

Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5

Phytomedicine (Stuttgart), 2019-09, Vol.62, p.152950-152950, Article 152950

2019

Volltextzugriff (PDF)

Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model

Cancer letters, 2020-11, Vol.492, p.174-184

2020

Volltextzugriff (PDF)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

The Lancet (British edition), 2018-12, Vol.392 (10162), p.2378-2387

2018

Volltextzugriff (PDF)

Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response

Neuron (Cambridge, Mass.), 2018-09, Vol.99 (5), p.914-924.e3

2018

Volltextzugriff (PDF)

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

The Lancet (British edition), 2020-02, Vol.395 (10222), p.427-440

2020

Volltextzugriff (PDF)

Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy

Molecular cell, 2017-04, Vol.66 (1), p.141-153.e6

2017

Volltextzugriff (PDF)

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

Cancer cell, 2011-01, Vol.19 (1), p.101-113

2011

Volltextzugriff (PDF)

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial

The Lancet (British edition), 2016-07, Vol.388 (10042), p.343-355

2016

Volltextzugriff (PDF)

1 – 25 von 1.747

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieThe Journal Of Biological Chemistry

ThemaBiological And Medical Sciences

KollektionScienceDirect Journals (5 years ago - present)

ThemaFemale

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.732)
Mit Volltextzugriff
(1.730)

Publikationsform

Artikel
(1.747)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.626)
Life Sciences & Biomedicine
(1.615)
Male
(1.221)
Middle Aged
(956)
Adult
(900)
Aged
(543)
Immunology
(432)
Tnf-Α
(400)
Tumor Necrosis Factor-Tnf
(324)
Animals
(295)
Young Adult
(250)
Cytokines
(246)
Treatment Outcome
(246)
Adolescent
(241)
Inflammation
(238)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(229)
Biochemistry & Molecular Biology
(220)
Cell Biology
(201)

13 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro-inflammatory “FADDosome” Complex upon TRAIL Stimulation

Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model

The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2

TNF-alpha inhibition for the treatment of cardiac sarcoidosis

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5

Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial

Aktive Filter

Suchergebnisse filtern